Trial participants invited to “Meet the Scientist” in Denver, attend MRF Gala

Meet the Scientist: Your Chance to Speak with the Mind Behind the COLUMBUS Phase 3 Trial in BRAF-Mutant Melanoma

Were you recently enrolled in a Phase III clinical trial evaluating an investigational BRAF+ targeted therapy combination? If so, there’s a chance you were a part of the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453) — which is studying the combination of LGX818 plus MEK162 versus vemurafenib and LGX818 monotherapy — and we’d love to hear from you.

Array BioPharma, the sponsor of the study and recipient of this year’s Corporate Leadership Award at our Wings of Hope for Melanoma gala in Denver on April 19, is inviting trial participants to its Boulder campus to meet with the scientist who co-developed one of the investigational agents: binimetinib (MEK162). If you were a part of the COLUMBUS study, take advantage of this unique opportunity to meet the chemist that discovered this compound, and learn how it went from discovery to clinical trial.

Array would also love to hear from you, and capture on film your perspectives on what matters most to the melanoma community. The company hopes that through this event, we can come up with ways to together make a difference in the lives of people living with melanoma.

DATE: Wednesday, April 18, 2018
TIME: 11 AM – 3 PM MDT
LOCATION: Array BioPharma, Boulder, CO
Travel, accommodation and meals will be covered for participants.

RSVP: Space is limited to 2 patients for this unique opportunity, so we ask that you RSVP by Wednesday, March 28 if you are interested and able to attend. The MRF Wings of Hope for Melanoma Denver gala will be held the following evening, April 19, at Mile High Station in Denver. If you are able to “Meet the Scientist” we would like to invite you to join the MRF and Array BioPharma for the gala, as well.

For more information or to RSVP, please contact Betsey Davis at [email protected] or 719.332.9078.